Qipian

Qipian is a polyvalent bacterial lysate tablet developed by Qilu Pharmaceutical. It is composed of inactivated lysates from three bacterial species: *Staphylococcus epidermidis*, *Moraxella catarrhalis* (formerly known as *Neisseria catarrhalis*), and *Bacillus subtilis*. Primarily utilized as an immunomodulatory add-on therapy for pediatric asthma and recurrent respiratory tract infections (RTI), Qipian works by shifting the immune response from a Th2-dominant allergic profile toward a Th1-dominant profile. This mechanism helps to reduce airway inflammation and hyper-responsiveness. Additionally, the drug enhances the production of secretory and serum immunoglobulins, including IgA, IgG, and IgM, which provides prophylactic protection against the respiratory infections that frequently trigger asthma exacerbations.

Brand names

Qipian

Other names

Staphylococcus and Neisseria tabletpolyvalent bacterial lysate